论文部分内容阅读
目的检测肺鳞状细胞癌患者化疗前后外周血单核细胞和B细胞膜表面FcγRⅡB表达水平、血清中可溶性FcγRⅡB(s FcγRⅡB)及其抗体的含量。方法免疫荧光技术检测鳞状细胞癌患者化疗前后单核细胞和B细胞膜表面FcγRⅡB的表达和定位、实时定量PCR检测FcγRⅡB mRNA水平,Western blot法检测s FcγRⅡB蛋白水平;ELISA检测鳞状细胞癌患者化疗前后、健康人血清中s FcγRⅡB总量、与Ig G结合的s FcγRⅡB(s FcγRⅡB-Ig G)、抗FcγRⅡB自身抗体的含量变化。结果与健康人相比,鳞状细胞癌患者化疗前单核细胞和B细胞FcγRⅡB的水平、s FcγRⅡB总量及抗FcγRⅡB自身抗体的含量明显降低,化疗后高于化疗前;s FcγRⅡB-Ig G含量高于健康人,化疗后低于化疗前。结论鳞状细胞癌患者FcγRⅡB含量减少,化疗后FcγRⅡB表达有所增加。
Objective To detect the expression of FcγRⅡB on peripheral blood mononuclear cells and B cell membrane in patients with squamous cell carcinoma of lung before and after chemotherapy and the content of soluble FcγRⅡB (sFγRⅡB) and its antibody in serum. Methods Immunofluorescence was used to detect the expression of FcγRⅡB on the surface of monocytes and B cells before and after chemotherapy. The expression of FcγRⅡB mRNA was detected by real-time PCR and the level of sFcyRIIB protein was detected by Western blot. The levels of FcγRⅡB protein in squamous cell carcinoma The levels of sFcyRIIB, sFcyRIIB (sFcyRIIB-IgG) and anti-FcyRIIB autoantibodies in healthy human serum before and after the change were measured. Results Compared with healthy controls, the levels of FcγRⅡB, the total amount of sFcyRIIB and the anti-FcyRIIB autoantibodies of monocytes and B cells in patients with squamous cell carcinoma before chemotherapy were significantly lower than those before chemotherapy after chemotherapy; sFcyRIIB-Ig G Content higher than healthy people, after chemotherapy lower than before chemotherapy. Conclusion The content of FcγRⅡB in patients with squamous cell carcinoma is decreased and the expression of FcγRⅡB is increased after chemotherapy.